[go: up one dir, main page]

MX9604309A - Aumento de la eficacia de drogas por deuteracion. - Google Patents

Aumento de la eficacia de drogas por deuteracion.

Info

Publication number
MX9604309A
MX9604309A MX9604309A MX9604309A MX9604309A MX 9604309 A MX9604309 A MX 9604309A MX 9604309 A MX9604309 A MX 9604309A MX 9604309 A MX9604309 A MX 9604309A MX 9604309 A MX9604309 A MX 9604309A
Authority
MX
Mexico
Prior art keywords
nifedipine
drugs
isotope
molecular
deuterated
Prior art date
Application number
MX9604309A
Other languages
English (en)
Other versions
MXPA96004309A (es
Inventor
Robert R Foster
Richard Lewanczuk
Gilles Caille
Original Assignee
Isotechnika Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isotechnika Inc filed Critical Isotechnika Inc
Publication of MX9604309A publication Critical patent/MX9604309A/es
Publication of MXPA96004309A publication Critical patent/MXPA96004309A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a un procedimiento para aumentar la eficacia de productos farmacéuticos o drogas conocidas y a las drogas mejoradas así producidas , por el cambio de la forma isotopica de la estructura molecular de la droga conocida. Más particularmente, la presente invencion se refiere a la modificacion de la estructura molecular de drogas conocidas, que contienen uno o más átomos de hidrogeno, por la deuteracion de uno o más de estos átomos de hidrogeno en átomos de deuterio. La droga resultante se altera significantemente y tiene una actividad mejorada sobre la droga conocida. Más
MXPA/A/1996/004309A 1994-03-25 1996-09-25 Aumento de la eficacia de drogas por deuteracion MXPA96004309A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21789794A 1994-03-25 1994-03-25
US217897 1994-03-25
PCT/CA1995/000154 WO1995026325A2 (en) 1994-03-25 1995-03-27 Enhancement of the efficacy of drugs by deuteration

Publications (2)

Publication Number Publication Date
MX9604309A true MX9604309A (es) 1998-05-31
MXPA96004309A MXPA96004309A (es) 1998-10-23

Family

ID=

Also Published As

Publication number Publication date
US5846514A (en) 1998-12-08
WO1995026325A3 (en) 1995-12-14
DE69535592D1 (de) 2007-10-25
KR20040068613A (ko) 2004-07-31
CN1087725C (zh) 2002-07-17
DE69535592T2 (de) 2008-06-12
CN1148843A (zh) 1997-04-30
JPH09510717A (ja) 1997-10-28
EP0751926A1 (en) 1997-01-08
WO1995026325A2 (en) 1995-10-05
BR9507200A (pt) 1997-09-16
AU1944195A (en) 1995-10-17
ATE372966T1 (de) 2007-09-15
KR100477070B1 (ko) 2006-04-21
CA2186371A1 (en) 1995-10-05
AU707748B2 (en) 1999-07-22
EP0751926B1 (en) 2007-09-12
JP3696884B2 (ja) 2005-09-21
ES2293638T3 (es) 2008-03-16

Similar Documents

Publication Publication Date Title
WO1995026325A3 (en) Enhancement of the efficacy of drugs by deuteration
WO1995026325B1 (en) Enhancement of the efficacy of drugs by deuteration
ATE314388T1 (de) Deuterierte und undeuterierte cyclosporin-analoga und ihre verwendung als immunmodulierende agentien
MY120279A (en) Use of a celecoxib composition for fast pain relief
BR9916857A (pt) 4 heteroaril diarilaminas
NZ502358A (en) Hydrogel composition comprising a biologically active substance combined with a macromer
FR2597851B1 (fr) Nouveaux borates mixtes a base de terres rares, leur preparation et leur application comme luminophores
EP0657486A3 (en) Fluorine-modified silicone, process for its production and cosmetics containing it.
FR2671083B1 (fr) Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques.
MXPA03007885A (es) Norbuprenorfina n-but-3-enilo y metodos de uso.
NZ509172A (en) Antimalarial agents
ATE283762T1 (de) Sauerstoffbindende zusammensetzung und methoden zu ihrer herstellung
BR9908211A (pt) Agente quìmico para melhorar as propriedades de engenharia dos solos
DK0821588T3 (da) Levobupivacain og anvendelse heraf som et anæstetikum til gravide kvinder
ITMI911038A0 (it) Processo per l'assorbimento di gas residui in particolare azoto, mediante una lega getter a base di bario non evaporato
DK1076561T3 (da) Kombinationsterapi til behandlingen af tumorer
MD970269A (en) Clavulanates
ES2150929T3 (es) Procedimiento para la obtencion de 3,7-dialquilxantinas a partir de 3-alquilxantinas.
DK9390D0 (da) Kondenserede benzapiner
DE4092406A1 (es)
CA2302033A1 (en) Methods and compositions for enhanced wound healing
ZA200205639B (en) Pseudopolymorph of (-)-cis-2-(chlorophenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy-1-methyl) piperidinyl]-4H-1-benzopyran-4-one.
李松 et al. Molecular Dynamic Studies on Nonquaternary Reactivators
BG104839A (en) Chrystalline form of paroxetine
WO2003024394A3 (en) Method of treating benign prostatic hyperplasia and other beingn porstate conditions